Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599810 | 0.98 | SPHK1 (0.63) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL3596842 | 0.89 | SPHK1 (0.60) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL3601901 | 0.89 | HTR2A (0.54) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7723203 | 0.89 | HTR2A (0.54) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7228646 | 0.82 | SPHK1 (0.50) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL3600688 | 0.82 | HTR2A (0.57) | HTR2AHTR2CHTR7HTR6KCNH2 | |
| SCHEMBL1457116 | 0.81 | HTR2A (0.64) | SPHK1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL14708456 | 0.81 | HRH3 (0.75) | HTR2AHTR2CHTR7HTR6KCNH2 | |
| SCHEMBL4079382 | 0.81 | HTR2A (0.60) | HTR2AHTR2CHTR7HTR6MAOA | |
| SCHEMBL13556830 | 0.81 | SPHK1 (0.63) | SPHK1HTR2AHTR2CHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | SPHK1 4111/4885HTR2A 263/4885HTR2C 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.